(48.55 g/L) was detected. She received treatment with three courses of chlorambucil and prednisone and responded well.

On current admission blood cell counts were as follows: hematocrit 22%, leukocytes 71.37 x 10^9/L (5% neutrophils, 92% lymphocytes with lymphoplasmacytic appearance), platelets 66 x 10^9/L. IgM paraprotein level was 60 g/L. Immunophenotype of the leukemic population gave the following results: CD5, CD19, CD23, CD22, CD20, CD25, cytoplasmic CD79a and FMC7 positive; CD10, CD103, CD38, BB-4 and CD11c negative. Smg expression in the membrane was strong (Figure 1).

A diagnostic problem that often arises is the differentiation of CLL with lymphoplasmacytoid features from lymphoplasmacytic lymphoma (LL) and splenic lymphoma with villous lymphocytes (SLVL). In all three diseases a paraprotein IgM can be found. LL should always be considered in cases of CD5/CD19/CD23 chronic lymphoproliferative disorders. Although rare, leukemic presentation can be misleading, especially if morphologic and clinical features are not so straightforward as in the case under discussion. Recently, immunophenotypic score systems have been proposed to differentiate between CLL and other chronic lymphoproliferative disorders. This distinction is clinically important since therapeutic implications are derived from a correct diagnosis. 1

Correspondence: Dr. Josep F. Nomdedéu, Secció de Marcadors, Departament d’Hematologia, Hospital de la Santa Creu i Sant Pau, Avda. Sant Antoni M. Claret 167 08025 Barcelona, Spain. Fax. international +34.3.2919192. E-mail: jfnomde@santpau.es

Leukemic meningitis in a patient with B-cell prolymphocytic leukemia

Sir, B-prolymphocytic leukemia (B-PLL) has become recognized as a morphologic variant of B-chronic lymphocytic leukemia (B-CLL). Its prognosis and response to treatment are less favorable than those of CLL, with a median of survival of three years. Clinical syndromes related to involvement of the central nervous system by mature B-cell leukemias are rare. To the authors’ knowledge, only six cases of meningeal involvement have been reported in B-PLL. Here we describe a case with a poor outcome in spite of intensive systemic and intrathecal therapy.

A 75-year-old woman was admitted in our Hospital in June 1995 because of general fatigue and weight loss. Physical examination showed splenomegaly of 3 cm below the costal margin. Laboratory data revealed: leukocytes 84.9 x 10^9/L with 85% prolymphocytes, hemoglobin 10.3 g/dL, platelets 116 x 10^9/L. Serological tests for hepatitis C virus were positive. Immunophenotyping of peripheral blood demonstrated monomoclonal B-lymphocytes expressing CD19 (95%), CD22 (95%), FMC7 (58%), CD5 (98%), CD10 (94%), CD23 (30%) and v light chain (strong). Bone marrow biopsy showed a diffuse infiltration by prolymphocytes. Thoracic and abdominal CT scans were normal. A diagnosis of B-PLL was made and treatment with chlorambucil and prednisone was given. Two weeks later the patient developed dizziness and diplopia. Neurologic examination showed left 6th nerve palsy without other motor deficiencies. A cerebral CT scan revealed no abnormalities. Lumbar punctures were traumatic and the cerebrospinal fluid (CSF) obtained was not useful for cytologic and biochemical analysis. Bacterial cultures were negative. An Ommaya reservoir was inserted in the patient and intraventricular treatment with weekly methotrexate, cytosine arabinoside and dexamethasone was started. At the same time, systemic chemotherapy with the CHOP regimen was also initiated. After the first cycle of intrathecal chemotherapy the patient showed a marked improvement in the neurologic picture and she became asymptomatic after six cycles. She did well until two months later when right 7th nerve palsy and somnolence developed. Physical examination and hematological studies were similar to those at initial diagnosis. At that time, a cerebral CT scan again showed no abnormalities. CSF analysis revealed an elevated protein content (450 mg/dL) with normal glucose. There were 20/μ prolymphocytes and 300/μ red blood cells. Notwithstanding a new dose of intrathecal therapy, the patient’s neurologic status worsened and she died two weeks later, four months after initial diagnosis.

Symptomatic meningeal involvement is a rare complication in mature B-cell malignancies. In our patient, meningeal leukemia was confirmed by the presence of prolymphocytes in the CSF and by the response to intrathecal therapy. The literature experience suggests that effective control of meningeal disease in mature B-cell leukemias can be achieved with intrathecal chemotherapy. However, the patient described here achieved only a transient complete response and died with uncontrolled meningeal leukemia.

Figure 1. Flow cytograms on peripheral blood.
References


Correspondence: Emilio Pastor, Servicio de Hematologia, Hospital "Lluis Alcanyis", Ctra. Xativa-Silla, km. 2, E-46800 Xativa (Valencia), Spain. E-mail: abd8861a5@colon.net